Company Overview - Shanghai Yinos Bio-Technology Co., Ltd. (Yinos) was established in 2010 and is a subsidiary of China National Pharmaceutical Group [3] - The company specializes in non-clinical safety evaluation and has obtained GLP certifications from NMPA, OECD, and FDA [4][10] - Yinos has a modern facility of over 72,000 square meters and a research team of over 1,000 people, providing comprehensive drug development services [4] Business Performance - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to 24 successful NDA/BLA cases and nearly 540 IND registrations [4] - Over 90% of the company's revenue comes from innovative drug research services, covering various drug types including oncology and gene therapy [9] New Quality Productivity - New quality productivity in the industry is driven by technological innovation, model reform, and talent upgrading, enhancing drug development efficiency and quality [6][8] - Key aspects include deep integration of cutting-edge technologies, iterative upgrades of full-chain service capabilities, and international compliance and standard output [7][8] R&D Investment - Yinos invested over 60 million yuan in R&D in 2024, focusing on innovative drug development despite a challenging financing environment [13] - The company has established various preclinical models and platforms to support drug efficacy evaluation and pharmacokinetics research [13][14] Strategic Direction - The company aims to strengthen independent R&D, build a high-end talent ecosystem, and deepen digital and global collaboration to cultivate new quality productivity [8] - Yinos emphasizes the importance of integrating traditional and emerging businesses to ensure a smooth transition during industry upgrades [10] Risk Management - Yinos has developed proactive risk management strategies, including early risk detection mechanisms and a closed-loop management system for risk prevention and response [12] - The company focuses on leveraging technological differentiation and agile organizational structures to convert industry pressures into opportunities [12]
董秘说|益诺思董秘李燕：新质生产力本质是通过技术创新、模式革新和人才升级推动药物研发跨越式提升！